Develops non-surgical, minimally invasive treatments for type 2 diabetes and related metabolic diseases by targeting the gut-brain axis.
Fractyl Health, Inc., a leader in metabolic therapeutics, focuses on pioneering treatments for type 2 diabetes (T2D) and obesity. At the forefront of its innovative approach is the Revita DMR System (Revita), an outpatient procedural therapy designed to address duodenal dysfunction a condition linked to high fat and high sugar diets that can trigger T2D and obesity in individuals.
In addition to Revita, Fractyl Health is advancing Rejuva, a groundbreaking platform based on adeno-associated virus delivery. This novel pancreatic gene therapy aims to achieve long-term remission of T2D and obesity by fundamentally altering metabolic hormone function within the pancreatic islet cells of patients.
Formerly known as Fractyl Laboratories Inc., the company underwent a name change to Fractyl Health, Inc. in June 2021. Founded in 2010 and headquartered in Burlington, Massachusetts, Fractyl Health continues to drive forward with its mission to revolutionize the treatment landscape for metabolic diseases through innovative therapeutic solutions.